Hub : Traits :

Medication: Blood pressure

139 significantly associated models · 68 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 5611729 7460433 4 1 9.9e-09 1.8e-08 3.0e-01 97 THAP3
2 1 11060075 12600396 3 2 4.4e-11 3.0e-13 4.5e-03 85 CLCN6 DRAXIN
3 1 112312154 113743567 1 1 7.3e-08 3.0e-13 4.3e-11 18 WNT2B
4 3 26563909 28211713 2 2 2.5e-14 6.9e-15 6.7e-02 94 SLC4A7
5 3 47518266 49365269 5 1 1.3e-08 9.4e-08 1.0e+00 100 ZNF589
6 4 80407869 82578407 2 2 2.9e-09 1.2e-36 8.9e-26 31 C4orf22 PRDM8
7 4 103020804 104627833 5 1 4.0e-08 5.6e-08 1.0e+00 100 CISD2
8 5 126596610 128116643 1 1 3.2e-07 2.3e-09 4.1e-04 65 CTC-228N24.3
9 7 6502367 7988091 1 1 1.6e-07 2.2e-05 3.8e-01 96 C1GALT1
10 10 95379543 96818402 1 1 7.8e-08 7.2e-08 1.9e-02 81 NOC3L
11 11 46033104 48783497 9 3 2.1e-09 7.2e-11 8.7e-03 84 AGBL2 NUP160 ZNF408
12 11 99859184 101559718 2 1 2.0e-17 9.3e-17 1.0e+00 100 ARHGAP42
13 11 110721187 112295421 2 1 5.4e-09 2.7e-09 1.0e+00 100 SIK2
14 12 89286081 90799212 1 1 8.3e-10 1.6e-12 2.5e-07 47 ATP2B1
15 12 111154626 113517494 5 1 3.2e-12 1.4e-18 1.7e-08 59 SH2B3
16 13 114302502 115106996 2 1 1.7e-07 3.7e-07 1.0e+00 100 CDC16
17 15 74042497 75930199 7 1 3.7e-11 5.5e-11 1.0e+00 100 CSK
18 15 80377452 81936479 1 1 2.9e-09 5.5e-10 6.7e-02 91 KIAA1199
19 15 90712555 92135418 2 1 1.5e-18 6.8e-17 5.2e-01 99 FES
20 17 45921906 48026049 6 3 3.9e-08 3.4e-12 5.5e-06 57 HOXB2 RP11-463M16.4 RP1-62O9.3
21 17 60858059 62259376 1 1 1.6e-09 7.4e-10 7.6e-02 92 ACE
22 20 7419920 9648826 1 1 6.4e-10 3.0e-19 8.1e-11 48 PLCB1
23 20 30083621 31469577 1 1 2.9e-09 1.4e-07 1.1e-05 30 TSPY26P
24 21 44251223 45879403 2 1 3.7e-08 1.0e-08 4.3e-02 88 PDXK

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (in father) 1.47 1 0 0.0 0.00 1.0e+00 ACE
Alzheimer’s Disease (including proxy) 1.95 2 1 3.0 0.00 1.0e+00 ACE RP1-62O9.3
Crohns Disease (2017) 1.07 1 0 0.0 0.00 1.0e+00 KIAA1199
Ulcerative Colitis (UC) 1.14 1 0 0.0 0.00 1.0e+00 CISD2
Major Depression (MDD) 1.99 2 0 0.0 0.00 1.0e+00 FES THAP3
Reaction Time 2.10 1 1 3.0 0.00 1.0e+00 SH2B3
Breast Cancer 4.01 4 1 3.0 0.18 7.7e-01 CSK FES SIK2 SLC4A7
Ovarian Cancer 2.06 1 0 0.0 0.00 1.0e+00 HOXB2
Coronary Artery Disease (CAD) 2.67 2 1 3.0 0.00 1.0e+00 RP11-463M16.4 SH2B3
Fasting Glucose 2.26 2 0 0.0 0.00 1.0e+00 AGBL2 CISD2
HDL Cholesterol 3.23 2 2 6.1 0.00 1.0e+00 AGBL2 ZNF408
LDL Cholesterol 1.57 2 0 0.0 0.00 1.0e+00 CSK SH2B3
Lupus 1.68 1 0 0.0 0.00 1.0e+00 CSK
Neuroticism 1.85 1 1 3.0 0.00 1.0e+00 NUP160
Primary Biliary Cirrhosis 1.96 2 1 3.0 0.00 1.0e+00 CISD2 SH2B3
Rheumatoid Arthritis 1.34 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia 2.04 3 1 3.0 0.00 1.0e+00 CISD2 FES THAP3
Type 2 Diabetes (T2D) 2.05 2 0 0.0 0.00 1.0e+00 CISD2 HOXB2
Blood Eosinophil Count 6.47 8 4 12.1 -0.64 8.7e-02 AGBL2 CDC16 CTC-228N24.3 PDXK RP1-62O9.3 SH2B3 SIK2 TSPY26P
Blood Platelet Count 1.69 8 3 9.1 0.15 7.0e-01 CLCN6 CSK PLCB1 RP11-463M16.4 SH2B3 SIK2 SLC4A7 WNT2B
Blood Red Count 2.04 9 5 15.2 -0.33 3.8e-01 C4orf22 CLCN6 CSK CTC-228N24.3 DRAXIN NUP160 PDXK SH2B3 ZNF589
Blood White Count 3.90 9 4 12.1 -0.79 1.2e-02 AGBL2 ARHGAP42 FES KIAA1199 NUP160 PLCB1 RP1-62O9.3 SH2B3 ZNF589
Heel T-Score 1.45 6 4 12.1 -0.07 8.9e-01 AGBL2 ARHGAP42 NUP160 SLC4A7 THAP3 ZNF408
BMI 1.73 10 3 9.1 -0.44 2.0e-01 C4orf22 CISD2 CSK KIAA1199 NUP160 RP11-463M16.4 RP1-62O9.3 THAP3 TSPY26P ZNF408
Height 1.45 15 13 39.4 0.55 2.9e-02 ACE AGBL2 ARHGAP42 CDC16 CTC-228N24.3 FES HOXB2 NOC3L NUP160 RP11-463M16.4 RP1-62O9.3 SH2B3 SLC4A7 WNT2B ZNF408
Waist Hip Ratio (WHR) 0.97 2 0 0.0 0.00 1.0e+00 AGBL2 SIK2
Systolic Blood Pressure 21.59 27 25 75.8 -0.96 1.5e-15 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 PDXK PLCB1 PRDM8 RP11-463M16.4 SH2B3 SIK2 SLC4A7 THAP3 WNT2B ZNF408 ZNF589
Smoking Status 1.67 3 0 0.0 0.00 1.0e+00 FES KIAA1199 RP11-463M16.4
Allergy or Eczema 2.27 6 1 3.0 0.35 4.9e-01 CISD2 CLCN6 CSK FES SH2B3 SIK2
Cardiovascular Disease 18.68 30 29 87.9 -0.98 2.2e-21 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 PDXK PLCB1 PRDM8 RP11-463M16.4 RP1-62O9.3 SH2B3 SIK2 SLC4A7 THAP3 TSPY26P WNT2B ZNF408 ZNF589
Hypothyroidism (self reported) 4.58 2 1 3.0 0.00 1.0e+00 SH2B3 ZNF589
Respiratory disease 1.49 2 0 0.0 0.00 1.0e+00 FES SIK2
Type 2 Diabetes (T2D) 2.15 4 0 0.0 -1.00 2.0e-03 ACE C1GALT1 RP11-463M16.4 SH2B3
Lung FEV1/FVC ratio 1.78 5 5 15.2 0.43 4.7e-01 ARHGAP42 ATP2B1 C1GALT1 THAP3 TSPY26P
Lung FVC 1.21 6 1 3.0 0.65 1.6e-01 C1GALT1 CTC-228N24.3 HOXB2 SH2B3 TSPY26P ZNF408
Neuroticism 1.87 2 1 3.0 0.00 1.0e+00 NUP160 ZNF408
Hair Pigment 0.72 12 7 21.2 0.27 4.0e-01 AGBL2 ARHGAP42 ATP2B1 C4orf22 CDC16 FES HOXB2 RP11-463M16.4 SH2B3 TSPY26P ZNF408 ZNF589
Tanning 0.35 4 1 3.0 -0.66 3.4e-01 CLCN6 CSK SH2B3 TSPY26P
Hand grip strength (left) 1.17 3 0 0.0 0.00 1.0e+00 FES HOXB2 WNT2B
Number of treatments/medications taken 6.00 9 3 9.1 0.96 3.0e-05 ACE ARHGAP42 C1GALT1 CISD2 FES KIAA1199 SH2B3 SLC4A7 TSPY26P
Sensitivity / hurt feelings 1.45 2 0 0.0 0.00 1.0e+00 CISD2 FES
Frequency of depressed mood in last 2 weeks 1.46 1 0 0.0 0.00 1.0e+00 NUP160
Relative age of first facial hair 1.37 1 1 3.0 0.00 1.0e+00 C4orf22
Other serious medical condition/disability diagnosed by doctor 1.15 1 0 0.0 0.00 1.0e+00 CSK
Systolic blood pressure, automated reading 13.62 22 16 48.5 0.97 8.5e-15 AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 RP11-463M16.4 SH2B3 SLC4A7 THAP3 WNT2B ZNF408 ZNF589
Angina 3.95 4 1 3.0 1.00 4.1e-04 FES RP11-463M16.4 RP1-62O9.3 TSPY26P
Medication: Metformin 1.89 1 0 0.0 0.00 1.0e+00 CISD2
Impedance of leg (right) 2.53 8 6 18.2 0.14 7.5e-01 ARHGAP42 CTC-228N24.3 FES KIAA1199 NOC3L RP11-463M16.4 RP1-62O9.3 SIK2
Leg fat-free mass (left) 1.50 6 3 9.1 -0.72 1.0e-01 ARHGAP42 CDC16 CTC-228N24.3 FES KIAA1199 SH2B3
Trunk fat percentage 1.62 6 0 0.0 0.39 4.5e-01 ACE CDC16 NOC3L NUP160 THAP3 ZNF408
Hand grip strength (right) 1.22 2 0 0.0 0.00 1.0e+00 HOXB2 WNT2B
Fed-up feelings 2.30 3 1 3.0 0.00 1.0e+00 NUP160 SH2B3 ZNF408
Taking other prescription medications 2.91 5 1 3.0 1.00 4.4e-05 CISD2 KIAA1199 RP1-62O9.3 SH2B3 TSPY26P
Age when periods started (menarche) 1.18 1 0 0.0 0.00 1.0e+00 CDC16
Heel bone mineral density (BMD) T-score, automated (left) 1.55 3 0 0.0 0.00 1.0e+00 ARHGAP42 THAP3 ZNF408
High blood pressure 19.81 30 25 75.8 0.98 6.7e-23 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 PDXK PLCB1 PRDM8 RP11-463M16.4 RP1-62O9.3 SH2B3 SIK2 SLC4A7 THAP3 TSPY26P WNT2B ZNF408 ZNF589
Hayfever, allergic rhinitis or eczema 2.25 3 1 3.0 0.00 1.0e+00 CSK FES SIK2
Supplements: Glucosamine 1.97 2 0 0.0 0.00 1.0e+00 CSK DRAXIN
Medication: Atenolol 7.56 6 2 6.1 0.99 6.3e-05 ARHGAP42 C1GALT1 C4orf22 FES SH2B3 WNT2B
Medication: Levothyroxine sodium 3.58 1 1 3.0 0.00 1.0e+00 SH2B3
Sitting height 1.41 6 4 12.1 0.37 4.2e-01 CDC16 KIAA1199 NUP160 RP11-463M16.4 SLC4A7 ZNF408
High blood pressure (mother) 8.31 9 2 6.1 0.98 6.0e-07 ARHGAP42 C4orf22 CLCN6 DRAXIN FES NUP160 RP11-463M16.4 SLC4A7 THAP3
Body mass index (BMI) 1.46 5 1 3.0 0.68 2.1e-01 KIAA1199 NUP160 RP11-463M16.4 THAP3 ZNF408
Impedance of leg (left) 2.66 9 6 18.2 0.06 8.8e-01 ARHGAP42 CTC-228N24.3 FES KIAA1199 NOC3L RP11-463M16.4 RP1-62O9.3 SIK2 SLC4A7
Leg predicted mass (left) 1.50 6 3 9.1 -0.72 1.1e-01 ARHGAP42 CDC16 CTC-228N24.3 FES KIAA1199 SH2B3
Trunk fat mass 1.39 4 0 0.0 0.56 4.4e-01 CDC16 KIAA1199 NOC3L THAP3
Waist circumference 1.45 3 2 6.1 0.00 1.0e+00 CSK KIAA1199 THAP3
Number of incorrect matches in round 1.87 3 0 0.0 0.00 1.0e+00 FES NUP160 ZNF408
Past tobacco smoking 1.88 1 0 0.0 0.00 1.0e+00 SH2B3
Alcohol usually taken with meals 1.42 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.22 1 0 0.0 0.00 1.0e+00 NUP160
Frequency of tenseness / restlessness in last 2 weeks 1.25 1 0 0.0 0.00 1.0e+00 NUP160
Hearing difficulty/problems with background noise 1.90 1 0 0.0 0.00 1.0e+00 CSK
Hair/balding pattern: Pattern 2 2.53 2 1 3.0 0.00 1.0e+00 C4orf22 PRDM8
Forced vital capacity (FVC) 1.67 5 0 0.0 -1.00 2.3e-05 CDC16 CTC-228N24.3 HOXB2 WNT2B ZNF408
Heel bone mineral density (BMD) T-score, automated (right) 1.38 3 0 0.0 0.00 1.0e+00 ARHGAP42 THAP3 ZNF408
Heart attack 2.94 2 1 3.0 0.00 1.0e+00 FES SH2B3
Allergy 2.57 3 1 3.0 0.00 1.0e+00 CISD2 FES SIK2
Diabetes (self-reported) 2.02 3 0 0.0 0.00 1.0e+00 ACE C1GALT1 CISD2
Medication: Ramipril 7.13 5 2 6.1 0.99 1.2e-03 ARHGAP42 CISD2 CSK FES NUP160
Medication: Simvastatin 4.79 4 1 3.0 0.99 9.1e-03 ARHGAP42 FES SIK2 THAP3
Illnesses of siblings 5.61 6 0 0.0 -0.99 5.6e-05 ARHGAP42 C1GALT1 FES RP11-463M16.4 SH2B3 ZNF589
Neuroticism score 1.68 1 1 3.0 0.00 1.0e+00 NUP160
Weight 1.22 4 2 6.1 0.44 5.6e-01 CDC16 KIAA1199 SH2B3 THAP3
Impedance of arm (right) 1.69 8 2 6.1 -0.58 1.0e-01 CISD2 KIAA1199 NOC3L RP11-463M16.4 RP1-62O9.3 SH2B3 SLC4A7 TSPY26P
Arm fat percentage (right) 1.73 4 2 6.1 0.60 4.0e-01 ACE NUP160 THAP3 ZNF408
Trunk fat-free mass 1.43 7 2 6.1 -0.19 6.6e-01 ARHGAP42 CDC16 CTC-228N24.3 HOXB2 KIAA1199 SH2B3 SLC4A7
Hip circumference 1.52 6 2 6.1 -0.09 8.6e-01 CDC16 CLCN6 KIAA1199 SH2B3 THAP3 ZNF408
Alcohol intake versus 10 years previously 1.33 1 0 0.0 0.00 1.0e+00 PDXK
Father's age at death 2.95 4 2 6.1 -0.99 1.1e-02 CSK FES NOC3L SH2B3
Frequency of tiredness / lethargy in last 2 weeks 1.49 1 0 0.0 0.00 1.0e+00 NUP160
Falls in the last year 1.56 1 0 0.0 0.00 1.0e+00 NUP160
Hair/balding pattern: Pattern 3 2.53 2 1 3.0 0.00 1.0e+00 C4orf22 PRDM8
Number of live births 1.39 1 0 0.0 0.00 1.0e+00 CISD2
Forced expiratory volume in 1-second (FEV1) 1.90 7 1 3.0 -0.98 6.5e-05 ARHGAP42 C1GALT1 CDC16 CTC-228N24.3 HOXB2 TSPY26P ZNF408
Qualifications: A levels/AS levels or equivalent 0.86 1 0 0.0 0.00 1.0e+00 CSK
Asthma 2.13 1 1 3.0 0.00 1.0e+00 SIK2
Medication: Ibuprofen (e.g. Nurofen) 1.33 1 0 0.0 0.00 1.0e+00 CSK
Medication: Cholesterol lowering 5.76 6 1 3.0 0.99 5.6e-05 ARHGAP42 C1GALT1 CSK FES SIK2 THAP3
Medication: Lansoprazole 1.17 1 0 0.0 0.00 1.0e+00 SH2B3
Illnesses of mother 5.05 4 1 3.0 -0.98 2.2e-02 ARHGAP42 FES NUP160 SLC4A7
Forced expiratory volume in 1-second (FEV1), Best measure 1.89 6 1 3.0 -0.97 9.9e-04 ARHGAP42 C1GALT1 CDC16 HOXB2 TSPY26P ZNF408
Pulse wave Arterial Stiffness index 2.48 2 0 0.0 0.00 1.0e+00 CLCN6 DRAXIN
Impedance of arm (left) 1.82 8 3 9.1 -0.57 1.1e-01 CISD2 KIAA1199 NOC3L RP11-463M16.4 RP1-62O9.3 SH2B3 SLC4A7 TSPY26P
Arm fat mass (right) 1.40 3 0 0.0 0.00 1.0e+00 KIAA1199 NUP160 THAP3
Trunk predicted mass 1.41 7 2 6.1 -0.19 6.5e-01 ARHGAP42 CDC16 CTC-228N24.3 HOXB2 KIAA1199 SH2B3 SLC4A7
Standing height 1.33 11 6 18.2 -0.53 7.7e-02 AGBL2 CDC16 CTC-228N24.3 HOXB2 NUP160 RP11-463M16.4 RP1-62O9.3 SH2B3 SLC4A7 WNT2B ZNF408
Tense / 'highly strung' 1.18 1 0 0.0 0.00 1.0e+00 NUP160
Hair/balding pattern: Pattern 4 3.29 3 1 3.0 0.00 1.0e+00 C4orf22 FES PRDM8
Birth weight of first child 4.67 5 3 9.1 -0.99 1.2e-03 CLCN6 CSK CTC-228N24.3 FES SH2B3
Peak expiratory flow (PEF) 1.47 1 0 0.0 0.00 1.0e+00 C1GALT1
Blood clot in the leg (DVT) 1.37 1 0 0.0 0.00 1.0e+00 SH2B3
Headache pain in last month 1.78 1 0 0.0 0.00 1.0e+00 CISD2
Medication for cholesterol, blood pressure or diabetes 15.26 27 13 39.4 -0.99 7.7e-26 ACE ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTC-228N24.3 DRAXIN FES KIAA1199 NOC3L PDXK PLCB1 PRDM8 RP11-463M16.4 RP1-62O9.3 SH2B3 SIK2 SLC4A7 THAP3 TSPY26P WNT2B ZNF408 ZNF589
Gout (self-reported) 1.29 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 3.95 1 1 3.0 0.00 1.0e+00 SH2B3
Medication: Amlodipine 9.87 12 6 18.2 0.96 3.5e-07 AGBL2 ARHGAP42 ATP2B1 CLCN6 FES HOXB2 KIAA1199 NOC3L SLC4A7 TSPY26P WNT2B ZNF408
Birth weight 2.56 3 3 9.1 0.00 1.0e+00 FES SH2B3 SIK2
Chronic bronchitis/emphysema (mother) 1.93 1 0 0.0 0.00 1.0e+00 SIK2
High blood pressure (siblings) 7.29 9 1 3.0 0.99 8.5e-07 AGBL2 ARHGAP42 C1GALT1 CLCN6 FES KIAA1199 PDXK SH2B3 SLC4A7
Forced vital capacity (FVC), Best measure 1.60 5 2 6.1 -1.00 2.2e-04 CDC16 CTC-228N24.3 HOXB2 WNT2B ZNF408
Body fat percentage 1.76 9 1 3.0 0.19 6.2e-01 ACE C1GALT1 C4orf22 CLCN6 NOC3L NUP160 SLC4A7 THAP3 ZNF408
Leg fat percentage (right) 2.12 5 2 6.1 0.69 2.0e-01 CLCN6 CTC-228N24.3 NOC3L THAP3 ZNF408
Arm fat-free mass (right) 1.32 4 2 6.1 0.36 5.5e-01 CDC16 KIAA1199 SH2B3 SLC4A7
Exposure to tobacco smoke outside home 1.28 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 1.68 3 0 0.0 0.00 1.0e+00 AGBL2 THAP3 ZNF589
Wheeze or whistling in the chest in last year 1.75 1 1 3.0 0.00 1.0e+00 SIK2
Pulse wave peak to peak time 2.63 2 0 0.0 0.00 1.0e+00 CLCN6 DRAXIN
Medication for pain relief, constipation, heartburn 2.17 4 0 0.0 -0.99 5.1e-03 ACE CISD2 KIAA1199 PRDM8
Angina (self-reported) 3.93 4 1 3.0 1.00 4.3e-04 FES RP11-463M16.4 RP1-62O9.3 TSPY26P
Medication: Allopurinol 1.28 1 0 0.0 0.00 1.0e+00 SH2B3
Mean time to correctly identify matches 2.54 2 1 3.0 0.00 1.0e+00 FES SH2B3
Reproduciblity of spirometry measurement using ERS/ATS criteria 0.94 1 0 0.0 0.00 1.0e+00 CDC16
Whole body fat mass 1.40 3 1 3.0 0.00 1.0e+00 CDC16 KIAA1199 THAP3
Leg fat mass (right) 1.50 3 1 3.0 0.00 1.0e+00 KIAA1199 THAP3 ZNF408
Arm predicted mass (right) 1.35 5 2 6.1 0.06 9.1e-01 CDC16 HOXB2 KIAA1199 SH2B3 SLC4A7
Pulse rate, automated reading 1.13 3 0 0.0 0.00 1.0e+00 C4orf22 SIK2 WNT2B
Comparative height size at age 10 1.44 7 3 9.1 -0.45 3.1e-01 AGBL2 C4orf22 CDC16 FES KIAA1199 SH2B3 ZNF408
Suffer from 'nerves' 1.53 1 1 3.0 0.00 1.0e+00 NUP160
Overall health rating 2.52 6 0 0.0 1.00 4.1e-06 C1GALT1 CISD2 RP11-463M16.4 RP1-62O9.3 TSPY26P ZNF408
Chest pain or discomfort 1.53 1 0 0.0 0.00 1.0e+00 C1GALT1
Medication: Aspirin 5.33 6 1 3.0 0.99 4.6e-05 FES PRDM8 RP11-463M16.4 SH2B3 SIK2 ZNF589
Hypertension (Self-reported) 20.14 30 25 75.8 0.98 2.5e-23 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 PDXK PLCB1 PRDM8 RP11-463M16.4 RP1-62O9.3 SH2B3 SIK2 SLC4A7 THAP3 TSPY26P WNT2B ZNF408 ZNF589
Illnesses of father: Heart disease 3.71 4 1 3.0 1.00 3.5e-03 FES RP1-62O9.3 SH2B3 SIK2
Smoking status: Previous 1.72 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.34 1 0 0.0 0.00 1.0e+00 CDC16
Whole body fat-free mass 1.43 7 3 9.1 -0.21 6.1e-01 ARHGAP42 CDC16 CTC-228N24.3 HOXB2 KIAA1199 SH2B3 SLC4A7
Leg fat-free mass (right) 1.58 7 3 9.1 -0.41 3.6e-01 ARHGAP42 CDC16 CTC-228N24.3 FES KIAA1199 SH2B3 SLC4A7
Arm fat percentage (left) 1.69 4 2 6.1 0.63 3.7e-01 ACE NUP160 THAP3 ZNF408
Average weekly red wine intake 0.85 1 0 0.0 0.00 1.0e+00 CSK
Mood swings 1.85 1 1 3.0 0.00 1.0e+00 NUP160
Loneliness, isolation 1.88 2 1 3.0 0.00 1.0e+00 NUP160 SH2B3
Ever had bowel cancer screening 1.66 1 0 0.0 0.00 1.0e+00 SIK2
Diabetes diagnosed by doctor 2.24 2 0 0.0 0.00 1.0e+00 ACE CISD2
Mouth/teeth dental problems: Mouth ulcers 1.46 2 0 0.0 0.00 1.0e+00 SH2B3 SLC4A7
Medication for cholesterol 6.90 10 2 6.1 -0.99 7.9e-08 ACE ARHGAP42 C4orf22 CISD2 FES KIAA1199 PLCB1 SH2B3 TSPY26P WNT2B
Back pain experienced in last month 1.59 1 0 0.0 0.00 1.0e+00 ATP2B1
Breast cancer (self-reported) 2.83 1 1 3.0 0.00 1.0e+00 SLC4A7
Asthma (self-reported) 2.04 1 1 3.0 0.00 1.0e+00 SIK2
Osteoarthritis (self-reported) 1.73 2 0 0.0 0.00 1.0e+00 CSK SIK2
Medication: Aspirin 5.49 4 1 3.0 1.00 3.1e-04 FES PRDM8 RP11-463M16.4 SIK2
Illnesses of father: None of the above (group 1) 4.48 3 1 3.0 0.00 1.0e+00 CDC16 FES SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.49 3 0 0.0 0.00 1.0e+00 C1GALT1 CTC-228N24.3 ZNF408
Whole body water mass 1.42 7 4 12.1 -0.23 5.8e-01 ARHGAP42 CDC16 CTC-228N24.3 HOXB2 KIAA1199 SH2B3 SLC4A7
Leg predicted mass (right) 1.57 7 3 9.1 -0.41 3.6e-01 ARHGAP42 CDC16 CTC-228N24.3 FES KIAA1199 SH2B3 SLC4A7
Arm fat mass (left) 1.34 3 1 3.0 0.00 1.0e+00 KIAA1199 NUP160 THAP3
Number of self-reported non-cancer illnesses 5.70 7 2 6.1 0.98 7.4e-05 C1GALT1 CISD2 CLCN6 KIAA1199 RP1-62O9.3 SH2B3 SLC4A7
Miserableness 2.03 2 1 3.0 0.00 1.0e+00 NUP160 ZNF408
Guilty feelings 1.76 1 0 0.0 0.00 1.0e+00 NUP160
Ever taken oral contraceptive pill 1.57 1 0 0.0 0.00 1.0e+00 TSPY26P
Mother's age at death 2.23 1 0 0.0 0.00 1.0e+00 CLCN6
Eye problems/disorders: Glaucoma 1.33 1 0 0.0 0.00 1.0e+00 AGBL2
Medication: Blood pressure 12.36 19 11 33.3 0.99 7.4e-16 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CISD2 CLCN6 CSK FES KIAA1199 PDXK PLCB1 SH2B3 SIK2 SLC4A7 WNT2B ZNF408 ZNF589
High cholesterol (Self-reported) 2.93 2 0 0.0 0.00 1.0e+00 ARHGAP42 FES
Medication: Bendroflumethiazide 9.67 16 5 15.2 0.99 8.5e-14 AGBL2 ARHGAP42 ATP2B1 C1GALT1 CLCN6 CSK DRAXIN FES KIAA1199 NUP160 PLCB1 RP11-463M16.4 SH2B3 SIK2 SLC4A7 WNT2B
Medication: Lisinopril 7.01 7 0 0.0 0.99 4.3e-06 AGBL2 ARHGAP42 C4orf22 CSK SH2B3 SLC4A7 ZNF589
Illnesses of father: High blood pressure 7.55 11 1 3.0 0.98 1.6e-07 ACE ARHGAP42 ATP2B1 C4orf22 CDC16 CLCN6 FES NUP160 PLCB1 SH2B3 SLC4A7
Ever smoked 1.68 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 1.34 5 3 9.1 0.45 4.4e-01 CDC16 CTC-228N24.3 KIAA1199 SH2B3 SLC4A7
Leg fat percentage (left) 2.17 6 2 6.1 0.67 1.5e-01 C1GALT1 CLCN6 CTC-228N24.3 NOC3L THAP3 ZNF408
Arm fat-free mass (left) 1.41 4 2 6.1 0.33 5.9e-01 CDC16 KIAA1199 SH2B3 SLC4A7
Number of operations (self-reported) 1.90 1 0 0.0 0.00 1.0e+00 PRDM8
Diastolic blood pressure, automated reading 11.84 21 13 39.4 0.95 2.5e-11 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK DRAXIN FES KIAA1199 NOC3L NUP160 RP11-463M16.4 SH2B3 SIK2 WNT2B ZNF408 ZNF589
Myopia 1.60 1 0 0.0 0.00 1.0e+00 WNT2B
Vascular/heart problems diagnosed by doctor 19.52 30 26 78.8 -0.98 3.4e-23 ACE AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTC-228N24.3 DRAXIN FES HOXB2 KIAA1199 NOC3L NUP160 PDXK PLCB1 PRDM8 RP11-463M16.4 RP1-62O9.3 SH2B3 SIK2 SLC4A7 THAP3 TSPY26P WNT2B ZNF408 ZNF589
Pain experienced in last month 1.50 2 0 0.0 0.00 1.0e+00 KIAA1199 SH2B3
Heart attack/myocardial infarction (self-reported) 2.96 2 1 3.0 0.00 1.0e+00 FES SH2B3
Deep venous thrombosis (DVT) (self-reported) 1.40 1 0 0.0 0.00 1.0e+00 SH2B3
Heart disease (siblings) 2.18 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 1.93 9 5 15.2 -0.41 2.3e-01 ARHGAP42 CISD2 CTC-228N24.3 KIAA1199 NOC3L RP11-463M16.4 RP1-62O9.3 SIK2 SLC4A7
Leg fat mass (left) 1.53 2 1 3.0 0.00 1.0e+00 KIAA1199 THAP3
Arm predicted mass (left) 1.38 4 2 6.1 0.34 5.7e-01 CDC16 KIAA1199 SH2B3 SLC4A7

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 4 0.1146 1.83
GTEx Adipose Visceral Omentum 3 0.1473 1.84
GTEx Adrenal Gland 2 0.1373 1.90
GTEx Artery Aorta 6 0.2015 1.91
GTEx Artery Coronary 0 0.0000 1.76
GTEx Artery Tibial 6 0.1595 1.85
GTEx Brain Caudate basal ganglia 1 0.1087 1.74
GTEx Brain Cerebellar Hemisphere 0 0.0000 1.73
GTEx Brain Cerebellum 2 0.1009 1.85
GTEx Brain Cortex 0 0.0000 1.81
GTEx Brain Frontal Cortex BA9 1 0.1082 1.83
GTEx Brain Hippocampus 1 0.1908 1.76
GTEx Brain Hypothalamus 0 0.0000 1.61
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.73
GTEx Brain Putamen basal ganglia 1 0.1603 1.68
GTEx Breast Mammary Tissue 3 0.1520 1.83
GTEx Breast Mammary Tissue (Male) 1 0.0838 1.77
GTEx Breast Mammary Tissue (Female) 3 0.1825 1.88
GTEx Cells EBV-transformed lymphocytes 4 0.2811 1.71
GTEx Cells Transformed fibroblasts 9 0.2143 1.87
GTEx Colon Sigmoid 2 0.1368 1.77
GTEx Colon Transverse 1 0.0484 1.79
GTEx Esophagus Gastroesophageal Junction 2 0.1384 1.90
GTEx Esophagus Mucosa 6 0.1807 1.81
GTEx Esophagus Muscularis 2 0.0619 1.81
GTEx Heart Atrial Appendage 0 0.0000 1.75
GTEx Heart Left Ventricle 1 0.0654 1.77
GTEx Liver 0 0.0000 1.63
GTEx Lung 2 0.0696 1.88
GTEx Muscle Skeletal 5 0.1730 1.88
GTEx Nerve Tibial 1 0.0231 1.75
GTEx Ovary 2 0.2203 1.88
GTEx Pancreas 3 0.1838 1.79
GTEx Pituitary 1 0.0897 1.73
GTEx Prostate 2 0.2395 1.86
GTEx Skin Not Sun Exposed Suprapubic 4 0.1627 1.86
GTEx Skin Sun Exposed Lower leg 3 0.0824 1.82
GTEx Small Intestine Terminal Ileum 0 0.0000 1.75
GTEx Spleen 1 0.0709 1.78
GTEx Stomach 1 0.0688 1.93
GTEx Testis 3 0.0951 1.81
GTEx Thyroid 4 0.1000 1.83
GTEx Uterus 2 0.3527 1.75
GTEx Vagina 2 0.3150 1.86
GTEx Whole Blood 1 0.0502 1.79
METSIM Adipose 4 0.0868 1.66
NTR Blood 3 0.1249 1.73
ROSMAP Brain Pre-frontal Cortex 5 0.1139 1.85
YFS Blood 5 0.1083 1.69
CommonMind Brain Pre-frontal Cortex 8 0.1488 1.73
TCGA Breast Tumor 0 0.0000 1.73
TCGA Breast Normal 6 0.1426 1.69
TCGA Ovarian Tumor 3 0.1027 1.68
TCGA Prostate Tumor 7 0.2024 1.69